Get the Stockscreener App
8.06
0.49%
-0.04
After Hours:
8.37
0.31
+3.85%
Annovis Bio Inc stock is traded at $8.06, with a volume of 107.79K.
It is down -0.49% in the last 24 hours and down -4.73% over the past month.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
See More
Previous Close:
$8.10
Open:
$8.14
24h Volume:
107.79K
Relative Volume:
0.07
Market Cap:
$105.22M
Revenue:
-
Net Income/Loss:
$-56.20M
P/E Ratio:
-2.2577
EPS:
-3.57
Net Cash Flow:
$-39.97M
1W Performance:
+0.75%
1M Performance:
-4.73%
6M Performance:
-32.27%
1Y Performance:
-15.07%
1-Day Range:
$7.97
$8.30
1-Week Range:
$7.82
$8.5499
52-Week Range:
$4.53
$22.49
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
Annovis Bio files three new patents for combination therapies - TipRanks
Annovis Bio Files Patents for Neurodegenerative Combination Therapies - TipRanks
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra - GlobeNewswire
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra - StockTitan
Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom - Seeking Alpha
Longeveron Inc (LGVN-Q) QuotePress Release - The Globe and Mail
(ANVS) Long Term Investment Analysis - Stock Traders Daily
(ANVS) Technical Pivots with Risk Controls - Stock Traders Daily
Annovis Bio’s CEO to Present at H.C. Wainwright Global Investment Conference - MSN
Annovis Bio, Inc. (NYSE:ANVS) Receives $33.60 Average PT from Analysts - MarketBeat
Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Annovis Bio’s CEO to Present at H.C. Wainwright Global Investment Conference - MyChesCo
Annovis Bio Publishes Key Study on Posiphen Drug Across Species - MSN
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Roche’s Vabysmo success in phase III among July clinical updates - BioWorld Online
Annovis Bio, Inc.'s (NYSE:ANVS) market cap rose US$24m last week; individual investors who hold 56% profited and so did insiders - Simply Wall St
Annovis Bio, Inc. (NYSE:ANVS) surges 24%; retail investors who own 56% shares profited along with insiders - Yahoo Finance
Largest borrow rate increases among liquid names - TipRanks
Annovis Bio, Inc. Expected to Post Q3 2024 Earnings of ($0.38) Per Share (NYSE:ANVS) - MarketBeat
ANVS Stock Earnings: Annovis Bio Beats EPS for Q2 2024 - InvestorPlace
Vanguard Group Inc. Raises Stock Position in Annovis Bio, Inc. (NYSE:ANVS) - Defense World
Q3 2024 EPS Estimates for Annovis Bio, Inc. Increased by HC Wainwright (NYSE:ANVS) - Defense World
How to Take Advantage of moves in (ANVS) - Stock Traders Daily
Annovis Bio Reports Q2 2024 Financial Results and Business Progress - MyChesCo
The Globe and Mail - The Globe and Mail
Annovis Bio (NYSE:ANVS) Given "Buy" Rating at HC Wainwright - MarketBeat
Annovis Bio’s (NYSE: ANVS) Lead Compound Shows Synergistic Cognitive Enhancement - Barchart
HC Wainwright Reiterates “Buy” Rating for Annovis Bio (NYSE:ANVS) - Defense World
Annovis Bio Reports Second Quarter Financial Results and Provides Business Update - GlobeNewswire
Annovis Bio Reports Second Quarter Financial Results and Provides Business Update - StockTitan
Annovis Bio reports Q2 EPS (44c), consensus (63c) - TipRanks
Annovis Bio (NYSE:ANVS) Lifted to "Strong-Buy" at EF Hutton Acquisition Co. I - MarketBeat
Annovis Bio, Inc. (NYSE:ANVS) Receives $33.60 Consensus PT from Brokerages - MarketBeat
Annovis Bio, Inc. (NYSE:ANVS) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Annovis Bio (NYSE:ANVS) Upgraded at EF Hutton Acquisition Co. I - Defense World
Annovis Bio Inc (ANVS-N) QuotePress Release - The Globe and Mail
Annovis Bio shares jump on bullish EF Hutton rating - Investing.com
Johnson & Johnson (JNJ-N) QuotePress Release - The Globe and Mail
Novo Nordisk A/S ADR (NVO-N) QuotePress Release - The Globe and Mail
Annovis Bio Shows Synergistic Effect of Buntanetap and Dulaglutide in Alzheimer's Treatment - MyChesCo
Annovis Bio (NYSE: ANVS) Reports on Clinical Data Showing Lead Compound Combined with GLP-1 Agonist Enhances Cognition - Barchart
Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist - BioSpace
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities - GlobeNewswire
Sanofi-Aventis S.A. ADR (SNY-Q) QuotePress Release - The Globe and Mail
Lucrative Incentive for Biotechs as Global Alzheimer's - GlobeNewswire
Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist - GlobeNewswire
Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist - StockTitan
Trend Tracker for (ANVS) - Stock Traders Daily
IBN Announces Latest Episode of The Bell2Bell Podcast - GlobeNewswire
IBN Announces Latest Episode of The Bell2Bell Podcast Featuring Annovis Bio CEO Dr. Maria Maccecchini, Live from AAIC 2024 - Yahoo Finance
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):